Table 2 Reporting rate of CytoSure v3 and v2 oligo-arrays.

From: Exon-focused targeted oligonucleotide microarray design increases detection of clinically relevant variants across multiple NHS genomic centres

 

Total number of samples

Samples with likely pathogenic or pathogenic CNV

% samples with likely pathogenic or pathogenic CNV

Number of samples reporteda

Reporting rate (%)

CytoSure v2

16,830

2,276

13.5

4,006

23.80

CytoSure v3

2,845

519

18.24

805

28.29

  1. aNumber of samples classified as either VOUS, likely pathogenic or pathogenic.
Back to article page